Search
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIt was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Bordetella pertussis pertactin antigen
go.drugbank.com/drugs/DB10789ApprovedInvestigationalBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].
Mixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONMethscopolamine
go.drugbank.com/drugs/DB11315ApprovedThe oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Mixtures: Dallergy PE, Allergy DN PECategories: Drugs for Functional Gastrointestinal DisordersTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … to be approved for this specific patient population.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18. … [A190486] The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsAlvespimycin
go.drugbank.com/drugs/DB12442InvestigationalIt has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent.
Aminocaproic acid
go.drugbank.com/drugs/DB00513ApprovedInvestigationalAn antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Mixtures: Hae Yan ToothTioconazole
go.drugbank.com/drugs/DB01007ApprovedTioconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. … Tioconazole is an imidazole antifungal used to treat fungal and yeast infections. Topical formulations are used for ringworm, jock itch, athlete's foot, and tinea versicolor or "sun fungus".
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigational[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed … Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus.
Synonyms: 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)ureaCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesAmlexanox
go.drugbank.com/drugs/DB01025ApprovedWithdrawnAmlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis.
Categories: Drugs for Obstructive Airway Diseases